Novartis gains FDA approval for Afinitor® in advanced breast cancer marking a ... MarketWatch (press release) Basel, July 20, 2012 - The US Food and Drug Administration (FDA) has approved Afinitor® (everolimus) tablets* for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer (advanced HR+ breast ... |
